RAPID Coverage Pathway Streamlines Medicare Access to Breakthrough Devices

The Centers for Medicare and Medicaid Services (CMS) and the U.S. Food and Drug Administration (FDA) have launched the Regulatory Alignment for Predictable and Immediate Device (RAPID) coverage pathway. This initiative aims to facilitate Medicare coverage for breakthrough medical devices classified as Class II and Class III by the FDA. By aligning device review and reimbursement protocols more closely, the program seeks to streamline the process from FDA approval to Medicare reimbursement.

John Brooks, CMS Deputy Director and Chief Policy and Regulatory Officer, announced that the RAPID pathway intends to provide faster Medicare access to FDA-designated breakthrough devices. Devices in this program could receive Medicare coverage within 60 to 90 days post-FDA approval, enhancing coordination between FDA and CMS. This approach allows manufacturers to understand early in the process what evidence is required to support Medicare coverage, starting from the Investigational Device Exemption (IDE) phase.

Since its inception in 2015, the FDA's Breakthrough Device designation has awarded over 1,200 designations. With this new system, CMS has temporarily suspended the Transitional Coverage for Emerging Technologies (TCET) program to prioritize implementing the RAPID coverage pathway. A CMS official emphasized that RAPID involves collaborative efforts with the FDA and manufacturers early in development stages, ensuring clinical data supports both FDA approval and Medicare coverage decisions, thereby reducing approval delays.

Grace Graham, FDA Deputy Commissioner for Policy, recognized the success of the Breakthrough program but noted concerns about Medicare coverage post-FDA clearance. The RAPID pathway addresses these by creating a seamless transition from approval to coverage. Devices under RAPID consideration must be part of an IDE study evaluating clinical health outcomes valued by both FDA and CMS, with approximately 40 current qualifying devices and an estimated additional 20 expected to participate.

According to Brooks, the initiative provides manufacturers with necessary guidance to align their development efforts with Medicare's requirements, improving investment timelines and potentially accelerating market access for life-saving devices. AdvaMed's President, Scott Whitaker, expressed optimism about expanding access to effective breakthrough medical technology among Medicare beneficiaries. Similarly, Mark Leahey of the Medical Device Manufacturers Association emphasized the program's promise to enhance timely access to new devices.

While the RAPID pathway draws comparisons to the parallel review process initiated in 2016, CMS aims to overcome inefficiencies noted in former models. Furthermore, CMS is refining its approach to New Technology Add-on Payments (NTAP) for breakthrough devices to ensure supported technologies demonstrate substantial clinical improvements. AdvaMed voiced concerns over potential NTAP repeals, stressing the importance of maintaining incentives for hospitals to adopt breakthrough technologies. Ongoing dialogue between industry stakeholders and CMS aims to optimize access to emerging health technologies.